We are live on ! Find out more
IPHA

Innate Pharma
IPHA

7 hedge funds and large institutions have $760K invested in Innate Pharma in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

75% more funds holding

Funds holding: 4 → 7 (+3)

1.54% less ownership

Funds ownership: 1.76% → 0.22% (-1.5%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

87% less capital invested

Capital invested by funds: $5.71M → $760K (-$4.95M)

Holders
7
Holders Change
+3
Holders Change %
+75%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$228K
2
Citadel Advisors
Citadel Advisors
Florida
+$113K
3
LPL Financial
LPL Financial
California
+$53.6K
4
Osaic Holdings
Osaic Holdings
Arizona
+$8.93K

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$5.46M
2
Millennium Management
Millennium Management
New York
-$22.2K
3
SPIA
Steward Partners Investment Advisory
New York
-$2.01K

IPHA Hedge Fund Activity: Q1 2021 in Review

7 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q1 2021, worth a combined $760K — down 87% from $5.71M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new IPHA positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $228K. The largest seller was Wellington Management Group, exiting entirely with an estimated $5.46M sold.

  • 7 institutional investors held Innate Pharma (IPHA) as of Q1 2021, up from 4 in Q4 2020.
  • Funds reported $760K of Innate Pharma stock for Q1 2021, down 87% quarter-over-quarter.
  • 4 funds opened new Innate Pharma positions in Q1 2021 and 1 closed out, a net change of +3 holders.
  • The largest Innate Pharma buyer in Q1 2021 was Morgan Stanley, an estimated $228K added.
  • The largest Innate Pharma seller in Q1 2021 was Wellington Management Group, an estimated $5.46M sold.

Based on aggregated 13F filings for Q1 2021.